taurocholic acid has been researched along with Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbas, C; Berenguer, J; Brochado-Kith, O; Díez, C; Fernández-Rodríguez, A; González-García, J; Hontañon, V; Jiménez-Sousa, MA; Martínez, I; Micán, R; Pérez-Latorre, L; Resino, S; Rojo, D; Virseda-Berdices, A | 1 |
| Bransford, P; Dworakowski, W; Kumar, S; Medek, A; Mudunuri, P; Peresypkin, A; Randles, EG; Snyder, PW; Song, B | 1 |
2 other study(ies) available for taurocholic acid and Hepatitis C
| Article | Year |
|---|---|
Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.
Topics: Antiviral Agents; Biomarkers; Female; Hepatitis C; HIV Infections; Humans; Inflammation; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Phosphatidylcholines; Severity of Illness Index; Spain; Taurocholic Acid | 2022 |
Overcoming the Bile Salt-Mediated Formation of Nanocolloids That Inhibit Oral Absorption of VX-985.
Topics: Administration, Oral; Animals; Antiviral Agents; Biological Availability; Colloids; Drug Carriers; Hepacivirus; Hepatitis C; Humans; Intestinal Absorption; Protease Inhibitors; Rats; Solubility; Spiro Compounds; Taurocholic Acid; Vitamin E | 2019 |